Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Schwarzach Im Pongau – page 2

20 clinical trials in Schwarzach Im Pongau, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Schwarzach Im Pongau at a glance
20
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

20 trials in Schwarzach Im Pongau

Open in trial search

Study on the Effectiveness and Safety of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Toddlers

Investigational
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:534
  • Sponsor:Sanofi Pasteur Inc.

Safety and immunogenicity study of Pentavalent Meningococcal ABCYW vaccine (MenPenta SD and MenPenta fHD) compared to licensed meningococcal vaccines in infants, toddlers and children

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · Healthy volunteers
  • Substances:Diphtheria toxoid
  • Sponsor:Sanofi Pasteur Inc.

Study on the Safety and Immune Response of MenABCWY Vaccine and Drug Combination in Healthy Infants with Meningococcal Infections

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · Healthy volunteers
  • Substances:GSKVX000000017986
  • Sponsor:GlaxoSmithKline Biologicals

Study on the Safety and Immune Response of a 21-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · Healthy volunteers
  • Substances:Pneumococcal oligosaccharide serotype 18C conjugated to CRM197
  • Sponsor:Sanofi Pasteur Inc.

Study on the Safety and Immune Response of MenABCWY Vaccine in Healthy Adolescents Aged 11-14 with Meningococcal Meningitis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · Healthy volunteers
  • Substances:MENINGOCOCCAL GROUP Y OLIGOSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197 PROTEIN
  • Sponsor:GlaxoSmithKline Biologicals

Study on the Safety and Immune Response of MenACYW Conjugate Vaccine Compared to a Drug Combination in Healthy Infants and Toddlers

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · Healthy volunteers
  • Substances:N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid
  • Sponsor:Sanofi Pasteur

Sleep disorder+1

Not recruiting

Study on Elinzanetant for Treating Sleep Disturbances in Menopausal Women

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Elinzanetant
  • Sponsor:Bayer AG

Hypophosphatasia

Not recruiting

Study on ALXN1850 for Adolescents and Adults with Hypophosphatasia Not Previously Treated with Asfotase Alfa

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:ALXN1850
  • Sponsor:Alexion Pharmaceuticals Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Schwarzach Im Pongau

What the registry says about research in the country

01 Stroke Prevention Research

Clinical research focusing on ischemic stroke prevention through innovative therapeutic approaches. The studies evaluate new treatments for patients who have experienced acute non-cardioembolic strokes or high-risk transient ischemic attacks.

  • Prevention strategies for recurring strokes
  • Post-stroke treatment optimization
  • Blood clot prevention therapies

The research investigates oral anticoagulation treatments combined with antiplatelet therapy, aiming to enhance protective measures against future stroke events.

02 Cardiovascular Medicine

Advanced studies in blood clot prevention are being conducted, specifically examining new compounds that target specific clotting factors. The research aims to improve outcomes for patients who have experienced mini-strokes.

  • Novel anticoagulation approaches
  • Blood clotting factor inhibition
  • Safety profile assessment

Researchers are evaluating the effectiveness of new therapeutic agents while carefully monitoring bleeding risk factors.

03 Neurological Disorders

Comprehensive research into transient ischemic attacks and their management, focusing on innovative preventive measures. The studies examine both immediate and long-term treatment strategies.

  • TIA risk management
  • Acute stroke intervention
  • Secondary prevention strategies

The research aims to establish more effective protocols for patients at high risk of recurring cerebrovascular events.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.